Health, Medical, Research, Science

Inoculation that protects against all strains of flu for 10 years

FLU-v JAB

A SINGLE jab which protects against all strains of flu for up to a decade could be available on the NHS in just two years.

The results of a UK human trial suggest the jab is more effective than existing vaccines which target only a few types of the virus.

Its creators claim it will end the scourge of flu globally, turning it into a mild illness rather than a killer.

The FLU-v jab, which is the work of British company Imutex, is said to fight off every strain, from the yearly winter virus to virulent strains such as swine flu and the recent Aussie flu. It is likely to cost between £20 to £50 per person but will need to be given only every five to ten years.

Current vaccines target proteins on the virus surface, but regions of these proteins constantly change in a bid to fool the immune system.

This means the virus is always one step ahead of the vaccine, which is why it must be remade each year. The new jab has been created to target unchanging regions of the virus proteins by boosting the immune system’s T-cells that recognise and attack foreign invaders.

The trial involved 123 participants aged 18 to 60 being infected with the H1N1 swine flu virus and spending eight days in a room. Eighty per cent were prevented from getting flu after having the jab. The vaccine was also twice as effective as limiting flu-like symptoms, with 60 per cent of those given the jab developing fewer than two symptoms. This suggests that even when people catch the flu virus, the vaccine can reduce the impact of its symptoms.

And a less severe infection for the elderly would slash the likelihood of complications and hospitalisations. After participants received FLU-v, their immune cells were tested against a range of flu strains. In all instances, the cells recognised and killed the virus.

It is hoped the results give the vaccine “breakthrough designation” from the US Food and Drug Administration – fast-tracking it through the approval process and paving the way for it to be available on the NHS within two years.

The new study was part of the collaboration with the National Institute of Allergy and Infectious Diseases, which is part of the world’s largest medical research establishment, the National Institute of Health in Washington, USA. The UK’s most senior influenza expert John Oxford, emeritus professor of virology at Queen Mary University of London, said: “I am enthusiastic about universal vaccines. It is recognised as being a good way forward.

“If one should have an effective universal flu vaccine, people could relax because you could have a dose of it and it would give years of protection against whichever virus is circulating.”

Dr Ed Schmidt, from the Universal Influenza Vaccine Consortium at Groningen University, Holland, said the vaccine could be “a game changer”, adding: “It would lead to a serious reduction in deaths and have a major impact.”

This winter, the annual jab worked in just a quarter of the population in what was deemed as the worst epidemic in seven years.

The NHS spends more than £100million annually on its flu vaccination programme alone.

A universal jab could save the NHS around £27,000 per person over the course of their lifetime from less illness, absences and reduced pressure.

Standard
Government, Health, Medical, Society

Antibiotic crisis is now a global emergency

WORLD HEALTH ORGANISATION

THE world is running out of effective antibiotics, health leaders have warned.

The problem is now a global emergency, the World Health Organisation (WHO) has said.

The growing resistance to drugs that fight infections could “seriously jeopardise” progress made in modern medicine, the WHO said. The remarks come after a WHO report found a serious lack of drugs in development that can overcome antibiotic resistance.

Health experts have already warned that resistance to antimicrobial drugs could cause a bigger threat to mankind than cancer. In recent years, there has been a UK drive to raise global awareness of the threat.

If antibiotics lose their effectiveness, then key medical procedures – including gut surgery, caesarean sections, joint replacements and chemotherapy – could become too dangerous to perform because of the increased infection risk.

Around 700,000 people around the world die each year because of drug-resistant infections including strains of tuberculosis, HIV and malaria. If no action is taken, it has been estimated that drug-resistant infections will kill 10million people a year by 2050.

 

Standard
Health, Medical, Research, Science

New heart drug offers biggest breakthrough since statins

MEDICAL RESEARCH

Unlike other treatments that tend to focus on cholesterol, Canakinumab works to lower inflammation in the body.

The discovery of a new heart drug is being hailed as the biggest breakthrough since statins. Thousands of lives could be saved.

In a four-year trial, scientists found that the drug – given by injection every three months – cut the risk of heart attacks by a quarter.

The study involving 10,000 patients, and around 1,000 doctors in 39 countries, also suggested that the drug could halve the risk of dying from lung cancer and prevent arthritis and gout.

Scientists said the treatment marked “a new era of therapeutics” that could save thousands of lives.

The drug, canakinumab, works by reducing inflammation – a major new approach in heart medicine. For the past 30 years cholesterol-busting statins have been given to nearly all people deemed to be at risk of cardiovascular disease in an effort to save them from heart attacks and strokes.

Yet half of the 200,000 people who have a heart attack in Britain each year do not have high cholesterol, so there is a desperate need for a different approach to treatment.

Experts have long thought that inflammation – the body’s natural responses to infection or injury – might also play a major role in causing heart attacks and strokes, possibly because it causes swelling in the arteries, increasing the risk of a blockage.

The new trial, however, is the first definitive proof that cutting inflammation slashes heart risk.

Study leader Professor Paul Ridker of Harvard Medical School said the new drug opened up a “third front” in the war on heart disease, following the previous focus on cholesterol and lifestyle.

Presenting his findings at the European Society of Cardiology congress in Barcelona, Professor Ridker said: “These findings represent the end game of more than two decades of research, stemming from a critical observation – half of heart attacks occur in people who do not have high cholesterol.

“We’ve been able to definitively show that lowering inflammation independent of cholesterol reduces cardiovascular risk.”

Professor Ridker, whose results are published in the New England Journal of Medicine, added: “This has far-reaching implications.

“It tells us that by leveraging an entirely new way to treat patients – targeting inflammation – we may be able to improve outcomes for certain very high-risk populations.”

Canakinumab is an antibody that attacks an immune-system protein called interleukin-1, which in high levels results in increased inflammation throughout the body.

The scientific trial involved high-risk patients who had already suffered a heart attack – a group in desperate need of help because a quarter of patients suffer a second attack within five years, even with statins.

All patients in the trial took statins as well, but canakinumab cut the risk of repeat heart attacks by 24 per cent, over and above the impact of the cholesterol drug.

People who took the drug were 36 per cent less likely to be hospitalised with unstable angina, and 32 per cent less likely to require costly bypass surgery.

Researchers reported a sharp rise in infections, which killed one in every 1,000 patients. But patients had a 51 per cent reduced risk of lung cancer deaths – a finding they said was “very exciting”. Gout and arthritis, which are linked to inflammation, also fell.

Canakinumab manufacturer Novartis said it would seek a licence to use the drug for heart disease.

Canakinumab is used for inflammatory problems, including forms of arthritis, at the cost of £9,928 per jab. Experts said the price – £40,000 a year for heart patients – would have to be lowered for it to be made available on the NHS.

Professor Jeremy Pearson, of the British Heart Foundation, said: “These exciting trial results finally confirm that ongoing inflammation contributes to risk of heart disease, and could help save lives.

Standard